Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
GLP-1 drugs before weight loss surgery: modest benefit, no extra risk
This meta-analysis of 5461 patients found that preoperative GLP-1 receptor agonist use led to moderate weight reduction (SMD 0.4, 4.87 kg vs…
Taking GLP-1 drugs before bariatric surgery helps drop a few extra pounds but doesn't boost long-term weight loss or raise complication risk…
Review of GLP-1RAs in Type 2 Diabetes and Atherosclerosis Mechanisms
Diabetes Drugs That May Protect Your Arteries From Clogging
This narrative review synthesizes evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Type 2 Diabetes and atherosclerosis. …
A class of diabetes drugs originally designed to lower blood sugar may also protect your arteries from the dangerous buildup that leads to h…
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
Expert meeting report reviews pharmacological strategies for acquired hypothalamic obesity
Could new drugs help patients with hypothalamic obesity finally control their hunger and lose weight?
An expert meeting report from Frankfurt am Main, Germany, discussed pharmacological strategies including dextroamphetamine, glucagon-like pe…
New drugs targeting hunger pathways show promise for patients with hypothalamic obesity, offering hope where diets and exercise have failed …
GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
Diabetes drugs work differently in women than men
A retrospective cohort study of 5.15 million adults with type 2 diabetes compared second-line therapies.
Diabetes drugs work differently for women than men, revealing distinct safety and effectiveness outcomes in a massive study of 5 million adu…
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
Could diabetes drugs help protect lungs? A new analysis of patient stories suggests a link
An analysis of 136 single-patient case reports from PubMed Open Access found that GLP-1 receptor agonist users had a lower risk of respirato…
Diabetes drugs linked to lower risk of serious lung problems in a new look at patient stories.